Bioton buys 18.6 percent of SciGen from Singapore

APA - Austria Presse Agentur
opublikowano: 03-10-2005, 14:28

Warsaw (Puls Biznesu) – Bioton, Poland’s listed insulin producer, signed an agreement with Scitech Genetics Pte Ltd to buy from it shares of SciGen Ltd. with headquarters in Singapore. Bioton will have 18.6 percent votes in this firm.

Warsaw (Puls Biznesu) – Bioton, Poland’s listed insulin producer, signed an agreement with Scitech Genetics Pte Ltd to buy from it shares of SciGen Ltd. with headquarters in Singapore. Bioton will have 18.6 percent votes in this firm.

This is part of Bioton’s strategy providing for strong presence is world market and changing the company into global player, Adam Wilczega, Bioton CEO said.Thanks to this acquisition, we have not only gained new distribution markets, but we have also managed to shorten the way to receive all necessary permissions to introduce our products into the market. I mean here human insulin and vaccine against jaundice, Wieslaw Walendziak, the deputy CEO of Prokom Investments, Bioton’s shareholder added.In the upcoming days, Bioton is going to announce another acquisition.

Poland/Enterprises/Healthcare

© ℗
Rozpowszechnianie niniejszego artykułu możliwe jest tylko i wyłącznie zgodnie z postanowieniami „Regulaminu korzystania z artykułów prasowych” i po wcześniejszym uiszczeniu należności, zgodnie z cennikiem.

Podpis: APA - Austria Presse Agentur

Polecane